Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Curie-Cancer and Biolog-id Sign Partnership Agreement

Published: Wednesday, June 05, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations.

Curie-Cancer and Biolog-id have announced a partnership to develop an RFID (Radio Frequency Identification) solution for use in tracking chemotherapy bags.

The collaboration aims to make it possible to comprehensively track chemotherapy preparations through the whole process, from centralized pharmacy preparation through to administration to patients in health care settings.

Within a multi-site hospital setting like the Institut Curie, the drug circuit is a structured process involving multiple functions.

The larger the number of steps (prescribing, preparing, dispensing and administering), clinical stakeholders (doctors, pharmacists, pharmacy technicians and nurses) and information and product flows, the more complex the process and the greater the potential for error.

Administering one particular patient's chemotherapy preparation to another patient may have tragic consequences, but it is incredibly rare.

A more common occurrence, however, is that a preparation intended for one health care department is routed to another.

The considerable cost of some cancer drugs and the disruption to activity within the department mean that this can have significant consequences.

Against a background of cost control and safety and quality in health care it is crucial for any technological response to reflect standard practice.

With extensive experience in the field of blood bag traceability, Biolog-id intends to apply its expertise to the monitoring and tracking of chemotherapy bags.

Based on a label that incorporates an electronic RFID tag and is affixed to every preparation, this innovation represents a technological breakthrough: tag information is updated automatically at different stages of the process (preparation, transportation and administration).

Preparations therefore become 'intelligent', offering the scope for storage of additional information, such as drug dosage, patient identity, stages in manufacture and inspection and routing.

The concept also aims to improve safety in health care over time by guaranteeing complete traceability for all unit dose preparations dispensed for a named individual, including parenteral nutrition, dialysis bags and other injectable preparations.

Biolog-id was therefore looking for a hospital facility with an interest in developing this type of solution and with the capacity for testing and allocating health care staff time to provide the clinical expertise required.

"We were interested in this idea right from the start," said Marion Lafay-Bourquin, pharmacist, and Christian Magne, manager within the Pharmacy department. "Over time one of the potential applications for this technology is in tracking preparations shared by the Institut Curie's different hospital sites."

The project involves over a dozen people, with the initial aim of defining the technical specifications for Biolog-id's proposed traceability solution in conjunction with medical staff, then testing it in parallel with the existing system.

Biolog-id's goal is to verify the pilot solution in place at the Institut Curie, then make it available to other institutions in France and worldwide.

"As an SME, it is not always easy to access academic expertise. However, to stay competitive, it is something we have to do," said Jean-Claude Mongrenier, chairman and CEO of Biolog-id.

Mongrenier continued, "There was an immediate rapport with Curie-Cancer, because they, like us, were aiming to improve the safety of patient care and reduce costs. In addition, they had a clear desire to help an SME and to support us in developing our plans, which we definitely appreciated."

"We are delighted to be able to contribute to the development of a French SME like Biolog-id," said Damien Salauze, director of Curie-Cancer "This is the essence of the Institut Carnot label which we were awarded by the French government in 2011 in recognition of our drive to provide concrete solutions for industry and ultimately for patients. Our partnerships usually involve a significant element of laboratory-based research work, but I am delighted that our expertise in hospital settings also addresses the requirements of other types of industrial partner."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.
Thursday, March 06, 2014
Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer
Preclinical program of translational research tasked with identifying new target proteins.
Wednesday, June 19, 2013
Curie-Cancer and Roche Strengthen Partnership
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Friday, May 17, 2013
Curie-Cancer and Vygon Sign a Partnership Agreement Extension
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.
Tuesday, April 16, 2013
Curie-Cancer and GenoSplice Technology Sign Bioinformatics Partnership Agreement
The innovative partnership is planned to run for several years to develop unique, high value added genomic approaches.
Wednesday, January 30, 2013
Curie-Cancer Funds its First Selection of Five Late-Stage Projects
Funding of these first five projects enables Institut Curie’s discoveries to progress more rapidly to the industrial stage, making innovation available to patients more quickly.
Friday, December 14, 2012
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Finding Links and Missing Genes
A catalogue of large-scale genetic changes around the world.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
A Natural History of Neurons
Diverse mutations reveal lineage of brain cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos